A potential role of karyopherin a2 in the impaired maturation of dendritic cells observed in glioblastoma patients

Konstantinos Gousias¹², Alexander von Ruecker³, Gerrit H. Gielen⁴, Pitt Niehusmann⁵, Andreas Waha⁶, Hartmut Vatter¹, Matthias Simon¹

¹Department of Neurosurgery, University Hospital of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.
²Department of Neurosurgery, University Hospital of Bochum, Bergmannsheil, Bärkli-de-la-Camp-Platz 1, 44789 Bochum, Germany
³Department of Pathology, University Hospital of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.
⁴Department of Neuropathology, University Hospital of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.

A B S T R A C T

Aim: Patients with glioblastomas demonstrate well-documented immunological impairments including decreased numbers of mature dendritic cells (DCs). Recent data identified karyopherin a2 (KPNA2), a nucleocytoplasmic shuttling receptor, as diagnostic and prognostic biomarker for gliomas. The aim of this ongoing study is to correlate parameters of immunity and nucleocytoplasmic transport in glioblastoma patients. Methods: We preoperatively collected serum from 17 patients with glioblastomas and determined DC subsets (HLA DR+ Lin−, CD34−, CD45+, CD123+, CD11c+ were analyzed) using a 6-color flow cytometry panel. Expression levels of KPNA2 and nuclear accumulation of p53 were evaluated semi-quantitatively by immunohistochemistry. O6-methylguanine DNA methyltransferase (MGMT) and isocitrate dehydrogenase-1 (IDH-1) status were assessed by pyrosequencing and immunohistochemistry, respectively. Results: Median expression levels for both KPNA2 and p53 were 5-10%. IDH-1-R132H mutation and MGMT promoter hypermethylation was detected in 3/16 and 1/9 patients, respectively. Mean counts of total mature DCs, myeloid DCs and plasmacytoid DCs were 9.6, 2.1, 3.4 cells/μL. A preliminary analysis suggests an association between low KPNA2 nuclear expression and increased numbers of mature DCs. However, this correlation did not reach statistical significance so far (P = 0.077). Conclusion: Our preliminary data may indicate a role of KPNA2 in the impaired maturation of DCs observed in glioblastoma patients.

Key words: Glioblastomas, isocitrate dehydrogenase-1, karyopherin a2, mature dendritic cells, O6-methylguanine DNA methyltransferase, p53

INTRODUCTION

Patients with glioblastomas demonstrate well-documented impairments of their immune system, including reduced values of mature dendritic cells (DCs).¹⁴ DCs is the most potent antigen-presenting cell population and therefore key regulators of adaptive immunity. Apart from their defense against infectious diseases they may also mediate antitumor responses.¹⁵,¹⁶ Their maturation/differentiation plays a pivotal role in their function. After recognizing and capturing antigens/tumor cells they undergo maturation, i.e., they upregulate major histocompatibility complex class II and co-stimulatory molecules at cell surface, they migrate to T cell rich zones and secrete cytokines to induce an antigen-specific T cell response.¹⁷

DCs maturation may be mediated by known signaling pathways/transcription factors, for instance, nuclear factor-κB (NF-κB), which is triggered after activation of the toll-like receptors (TLRs) by invading microorganisms.¹⁷ Once in the nucleus, NF-κB may induce the transcription of various genes involving in immune and inflammatory responses.¹⁸ Nuclear import of NF-κB is mediated by the karyopherin a2/importin unit 2 complex (KPNA2), a well-studied member of the family of karyopherins.¹⁹

Karyopherins are nucleocytoplasmatic shuttling receptors and comprise importins and exportins. They
have been linked to signal transduction pathways and cell cycle control mechanisms.\(^ {10-13}\) KPNA2 mediates the nuclear import of large molecules (> 40 kDa, most of the proteins and RNAs) by binding to a specific recognition sequence called the nuclear localization signal (NLS). After entering the nucleus, the NLS-containing macromolecule is dissociated by RanGTP and KPNA2 recycles back to the cytoplasm.

Recent data suggests a role for the nucleocytoplasmic transport, in particular for KPNA2, in gliomagenesis. We have previously identified low expression of KPNA2 as an independent prognostic factor for better overall survival (OS) and progression-free survival (PPS) in patients with infiltrative gliomas.\(^ {14,15}\) KPNA2 has been also recognized as a prognostic factor in patients with meningiomas\(^ {16}\) as well as in patients with other solid tumors.\(^ {17-20}\)

The aim of our work is to investigate the role of nucleocytoplasmic import and of other known biomarkers in the maturation procedure of DCs. In a recent work, we analyzed the preoperative phenotype of DCs in patients with gliomas.\(^ {21}\) In the present ongoing study we determined also parameters of nucleocytoplasmic import (KPNA2) as well as other glioma-associated molecular markers such as $O^6$-methylguanine DNA methyltransferase (MGMT) promoter hypermethylation, isocitrate dehydrogenase-1-R132H (IDH-1-R132H) gene mutation status and nuclear accumulation of p53 within the tissue specimens and analyzed a putative correlation between them.\(^ {21-23}\) Our preliminary results imply a possible role of KPNA2 in the known impaired maturation of DCs in patients with glioblastomas.

**METHODS**

**Patients and clinical characteristics**

We analyzed preoperatively collected fasting morning serum from 17 consecutive adult (median age: 54 years, range: 33-78 years; 58.8% male) patients with subsequently histologically confirmed de novo glioblastomas operated at the Department of Neurosurgery of the University Hospital of Bonn between November of 2010 and February of 2011 for DC subpopulations. In addition, surgical specimens from our patients were analyzed for expression of KPNA2 ($n = 16$) and nuclear accumulation $p53$ ($n = 17$) as well as for IDH-1-R132H mutation status ($n = 16$) and MGMT promoter hypermethylation ($n = 9$). Nonneoplastic brain tissues from two patients who underwent surgery for epilepsy served as controls. The circadian rhythm of the immunological parameters and the possible effect of dexamethasone administration were considered at the blood collection as previously described.\(^ {21}\)

All tumors were located in the supratentorial compartment. Three (17.6%) patients had a diagnostic biopsy only due to the eloquent location of the tumor and 35.3% of resections were gross total. All patients underwent chemo- and radiotherapy after surgery. The demographics of our study population are shown in Table 1. Patients with a history of previous brain tumor or other cancer, radio- or chemotherapy or of an immunological or hematological disease were excluded from the study. The patients’ samples were collected after their informed consents were obtained in accordance with the tenets of the declaration of Helsinki and approval of the study by the Ethics Committee of the Medical Faculty of the University of Bonn.

**Flow cytometry**

Dendritic cell and T-lymphocyte subpopulations values were determined by flow cytometry using six different fluorochromes: fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridininchlorophyllprotein (PerCP), allophycocyanin (APC), PE-Cy7 (PE-Cy7) and APC-Cy7. The following surface and intracellular anti-human monoclonal antibodies were used: CD45-APC Cy7 (clone 2D1), CD4-PE (clone RPA-T4), CD3-PerCP (clone SK7), HLA-DR-PerCP (clone L243), CD11c-APC clone (S-HCL-3), lineag-FITC (lin-1 cocktail), CD34-FITC (clone 8G12), CD123-PE-Cy7 (clone 6H6, ebioscience, San Diego, CA) as well as isotype controls.

Cells were surface stained according to the manufacturers’ protocols. DCs were isolated as previously described.\(^ {21}\) Briefly, DCs were gated as HLA-DR (MHC class II) positive, lineage-negative, CD34 negative, and CD45 positive (HLA DR+/lin-/CD34-/CD45+). DCs were further subclassified as myeloid DCs (mDCs) or plasmacytoid DCs (pDCs) based on their reciprocal

<table>
<thead>
<tr>
<th>Table 1: Patient demographics and tumor characteristics</th>
<th>Variable</th>
<th>Absolute numbers (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Median age (range)</td>
<td>54 (33-78) years</td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>10 (58.8)</td>
<td></td>
</tr>
<tr>
<td>Maximum tumor diameter $\leq 3$ cm</td>
<td>7 (41.1)</td>
<td></td>
</tr>
<tr>
<td>Resection**</td>
<td>6 (35.3)</td>
<td></td>
</tr>
<tr>
<td>STR</td>
<td>8 (47.0)</td>
<td></td>
</tr>
<tr>
<td>Biopsy</td>
<td>3 (17.6)</td>
<td></td>
</tr>
<tr>
<td>Preoperative KPS: 90-100%</td>
<td>12 (70.5)</td>
<td></td>
</tr>
<tr>
<td>Postoperative KPS: 90-100%</td>
<td>11 (64.7)</td>
<td></td>
</tr>
<tr>
<td>Preoperative seizures: yes</td>
<td>6 (35.3)</td>
<td></td>
</tr>
<tr>
<td>Elocence***: Yes</td>
<td>10 (58.8)</td>
<td></td>
</tr>
<tr>
<td>Radiotherapy: Yes</td>
<td>17 (100)</td>
<td></td>
</tr>
<tr>
<td>Chemotherapy: Yes</td>
<td>17 (100)</td>
<td></td>
</tr>
</tbody>
</table>

*Maximum tumor diameter has been defined as the longest (any) diameter of contrast enhancing mass area in postcontrast T1-weighted MRI datasets; **Extent of resection was classified according to the postoperative MRI (2-3 days after surgery); ***Tumors were categorized as eloquent if they were growing into the primary sensorimotor or visual cortex, Broca’s or Wernicke’s area/the dominant angular gyrus area, the basal ganglia, thalamus or internal capsule. MRI: magnetic resonance imaging; KPS: Karnofsky performance score.
expression of CD11c (a-integrin) and CD123 (IL-3 receptor a), respectively. Figures 1 and 2 of our previous publication illustrate the classification/gating steps.[4] HLA-DR, CD11c, CD45, CD123 are co-stimulatory surface molecules, which have been identified in the relevant literature as markers of maturation.[24-27] CD34 is a marker for all stem cells and the proportion of precursor DCs.[28] Therefore, HLA DR+/Lin-/CD34-/CD45- represent less mature DCs, whereas HLA DR+/Lin-/CD34-/CD45+/CD123+ mDCs and HLA DR+/Lin-/CD34+/CD45+/CD123+/CD11c- pDCs mature DCs in advanced stages of maturation.

Immunohistochemistry
Neuropathological analysis of glioblastomas comprised hematoxylin/eosin staining as well as immunohistochemistry with monoclonal antibodies directed against the microtubule-associated protein 2 (MAP2, Sigma, Steinheim, Germany), polyclonal antibodies directed against glial fibrillary acid protein (GFAP, Sigma, Steinheim, Germany) and monoclonal antibodies directed against Ki67 (MIB1, Dako, Glostrup, Denmark).

IDH-1-R132H mutation status (monoclonal mouse antibody H09 directed against mutated IDH-1 R132H mutation, Dianova, Hamburg, Germany) and KPNA2 immunoreactivity (goat polyclonal SC6917; Santa Cruz Biotechnology, Santa Cruz, USA; dilution 1:100) were assessed and visually scored independently by two experienced neuropathologists (PN, GHG) as previously described [Figure 1].[14] Immunohistochemical staining with a monoclonal antibody against p53 (clone DO-7, Dako, Glostrup, Denmark), in a dilution of 1:150, were performed on the Ventana Immunostainer (Roche, Mannheim, Germany), with a closed avidin-biotin complex Ventana Detection System (Ventana). Positive and negative controls were also performed using glioblastoma tissue with p53 overexpression [Figure 1].

Tumors were assigned to immunoreactivity classes of KPNA2 and p53 based on the percentage of moderately or strongly immunopositive cell nuclei (< 1%, 1%‑< 5%, 5%‑< 10%, 10%‑< 20%, 20%‑< 50% and ≥ 50%).

Pyrosequencing
The quantitative analysis of MGMT promoter methylation by pyrosequencing was performed as previously described.[29] Briefly, the first four CpG sites are assayed for a primer extension reaction. Methylated fractions > 10% at all positions define a methylated sample [Figure 2].

Statistical analysis
Statistical analyses of the data were performed using commercially available software (SSPS 21.0, IBM Deutschland, Ehningen, Germany). Comparisons of samples were performed using standard methods (Pearson’s Chi-square, Fisher’s exact test). P < 0.05 (two-tailed) were considered to be statistically significant.
significant. Cut-off values for nonparametric statistics were set at the median of each variable, that is, the studied subgroups were as following: KPNA2: < 5% vs. ≥ 5% positive cell nuclei; p53: < 5% vs. ≥ 5% positive cell nuclei; total mature DC: < 5.9 vs. ≥ 5.9 cells/μL; pDC: < 1.6 vs. ≥ 1.6 cells/μL; mDC: < 0.6 vs. ≥ 0.6 cells/μL; age: < 54 vs. ≥ 54; preoperative and postoperative Karnofsky performance index (KPI): < 90 vs. ≥ 90.

RESULTS

The relative proportions of total mature DCs as well as subsets of mature DCs in patients with glioblastomas were as following: total DCs as proportion of WBC: 0.11% (0.05-0.16%), pDC CD123+ CD11c- as proportion of total DCs: 28.3% (16.5-40.1%), mDC CD123- CD11c+ as proportion of total DC: 15.5% (6.0-25.1%), CD123-CD11c+ as proportion of total DCs: 54.5% (38.7-70.3%). Similarly, counts (mean, 95% CI, median) (cells/μL) of mature DCs were: total mature DCs: 9.6 (4.3-14.9), 5.9, pDC CD123+ CD11c-: 3.4 (1.1-5.8), 1.6, mDC CD123- CD11c+: 2.1 (0.6-3.6), 0.6 [Table 2].

Median expression levels for both KPNA2 and p53 were 5-10% [Figure 3]. IDH1-R132H mutations were detected in 3/16 patients. All glioblastoma patients with mutant IDH-R132H experienced a sudden onset (< 3 months) of their symptoms, which imply that these patients harbored primary rather than secondary glioblastomas. Representative results of KPNA2, p53- and IDH-1-immunohistochemistry are shown in Figure 1. MGMT promoter hypermethylation was observed in 1/9 tumors [Figure 2].

A preliminary analysis suggests an association between lower KPNA2 nuclear expression and increased numbers of mature DC. All patients with low KPNA2 (< 5%) expression and only 33.3% of patients with KPNA2 ≥ 5% demonstrated counts of mature DCs over the median (≥ 5.9 cells/μL). However, this correlation did not reach statistical significance so far (total mature DC ≥ 5.9 cells/μL: KPNA2 < 5% vs. ≥ 5%/100% vs. 33.3%, Pearson’s Chi-square: P = 0.038, Fisher’s exact test: P = 0.077, both two-sided; Fisher’s exact test is most appropriate, since study population is limited) [Figure 4].

A trend between KPNA2 expression and IDH-R132H mutation status has been observed. Patients expressing lower KPNA2 exhibit also frequently mutant IDH1-R132H (mutant IDH1-R132H: KPNA2 < 5% vs. ≥ 5%/66.7% vs. 7.7%, Pearson’s Chi-square: P = 0.018, Fisher’s exact test: P = 0.071, both two-sided) [Figure 4]. No mutant IDH1-R132H status was seen in patients with KPNA2 ≥ 10%. No other significant correlations between expressions of KPNA2, p53, MGMT promoter hypermethylation and IDH1-R132H mutation status have been observed.
No significant imbalances between subgroups of KPNA2 and p53 expression as well as MGMT promoter methylation and IDH-1 mutation status (see statistical analysis) with respect to age, gender, type of resection (resection vs. biopsy), preoperative and postoperative KPI, tumor volume, presence of epilepsy (yes/no), neurological deficits (yes/no) and eloquence of the tumor location (yes/no) were seen [Table 3].

DISCUSSION

Patients with glioblastomas exhibit well-documented immunological abnormalities; in particular, they demonstrate an impaired cellular immunity; that is, reduced counts of effector T helper and relative accumulation of suppressive T regulatory cells. The APC function of DCs, as reflected by the ability to stimulate allogeneic T cells, is also altered/diminished. Patients with glioblastomas demonstrate also reduced values of mature DCs compared to patients with gliomas WHO grade I-III or healthy donors.

The maturation of DCs is the key regulator of their APC function, comprises several stages (stem cells/precursors/poorly differentiated/highly differentiated not activated/highly differentiated and activated/apoptosis) and includes the up regulation in the nucleus of MCH highly differentiated and activated/apoptosis) and function, comprises several stages (stem cells/precursors/poorly differentiated/highly differentiated not activated/highly differentiated and activated/apoptosis).

Karyopherins are nuclear proteins involved in nucleocytoplasmatic shuttling and have been linked to tumorigenesis. KPNA2 has been identified as a regulator of DNA repair proteins and an activator of apoptosis pathways. Recent data suggested a role for KPNA2, also in gliomagenesis. We have recognized in two recent works about KPNA2 as an independent prognostic factor for OS and PFS in 94 patients with infiltrative astrocytomas WHO grade II-IV as well as in 72 patients with anaplastic gliomas (astrocytomas, oligoastrocytomas and oligodendrogliomas WHO grade III). KPNA2 has been also identified as a prognostic factor in patients with meningiomas as well as in patients with other solid tumors.

<table>
<thead>
<tr>
<th>Table 2: Relative proportions and counts of T-lymphocytes, T-helper lymphocytes and DC subsets in our series</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunological parameter</td>
</tr>
<tr>
<td>--------------------------</td>
</tr>
<tr>
<td>T cell lymphocytes CD3+ %WBC*</td>
</tr>
<tr>
<td>T helper lymphocytes CD4+ %WBC</td>
</tr>
<tr>
<td>DCS HLA DR+/CD34+/CD45+ %WBC</td>
</tr>
<tr>
<td>pDCs CD123+ CD11c-%DC**</td>
</tr>
<tr>
<td>mDCs CD123-, CD11c-%DC</td>
</tr>
<tr>
<td>CD123-, CD11c-%DC</td>
</tr>
</tbody>
</table>

* % WBC: relative proportion of WBCs; ** % DC: relative proportion of DCs; DCS: dendritic cells; WBC: white blood cell; CI: confidence interval; HLA: human leukocyte antigen; DR: diabetic retinopathy

<table>
<thead>
<tr>
<th>Table 3: Correlations between levels of immunoreactivity (p53 and KPNA2) and clinical characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variable</td>
</tr>
<tr>
<td>--------------</td>
</tr>
<tr>
<td>Males</td>
</tr>
<tr>
<td>Max tumor diameter ≤ 3 cm</td>
</tr>
<tr>
<td>Resection Cytoreductive surgery</td>
</tr>
<tr>
<td>Diagnistic biopsy</td>
</tr>
<tr>
<td>Preoperative KPS: 90-100%</td>
</tr>
<tr>
<td>Postoperative KPS: 90-100%</td>
</tr>
<tr>
<td>Preoperative seizures: yes</td>
</tr>
<tr>
<td>Eloquence: yes</td>
</tr>
</tbody>
</table>

* n.s: no significant; P > 0.05. KPNA2: karyopherin a2; KPS: Karnofsky performance score
In the present ongoing study, we determined and correlated DC subpopulations as well as expression of KPNA2 in patients with glioblastomas. Since KPNA2 is thought to mediate the nuclear import of certain transcription factors, which may induce the maturation of DCs, a certain correlation has been expected. Indeed, our preliminary analysis suggests an association between low KPNA2 nuclear expression and increased numbers of mature DCs. However, this correlation did not reach statistical significance so far (Fisher exact test, \( P = 0.077 \)) probably due to the limited studied population. The observed inverse correlation between KPNA2 expression and counts of mature DCs\(^4\) and decreased counts of mature DCs\(^4\) have been both found to characterize patients with malignant gliomas. The idea of the possible role of KPNA2 also in the regulation of the immunity of glioblastoma patients is tempting; in such a case an additional therapeutic target for the immunotherapy may have been identified.

To our best knowledge, this is the first study focusing on the role of importins in the maturation of DCs. Some evidence of a role of karyopherins (only exportins) in the function of DCs has been previously elucidated,\(^3\)\(^2\) Chemnitz et al.\(^1\) studied \textit{in vitro} the role of the exportin chromosome region maintenance protein 1/\textit{CRM1} in the maturation and activation of DCs. Inhibition of \textit{CRM1} by Leptomycin B down regulates the expression of the co-stimulatory molecule CD83 and abrogated the ability of allogeneic T cell stimulation.\(^3\)

Established prognostic molecular biomarkers, such as MGMT promoter methylation and IDH-1 mutation status were also included in our analysis. Patients with low KPNA2 expression exhibit frequently (not statistically significant) mutant IDH-1-R132H (Fisher’s exact test: \( P = 0.071 \)). The clinical history of the patients with mutant IDH-1-R132H status (sudden onset of symptoms < 3 months) does not suggest a secondary genesis of glioblastomas. However, a possible association between lower KPNA2 expression and genesis of secondary glioblastomas could not be excluded. An inverse correlation of KPNA2 expression and IDH-1 immunostaining in patients with malignant gliomas was found also previously.\(^4\)

Furthermore, we tested whether expression of KPNA2 and DC subpopulations correlated with clinical factors, such as gender, age, preoperative and postoperative Karnofsky Index, preoperative presence of seizures or neurological deficits, tumor diameter, tumor eloquence and degree of resection. No significant associations were found. We presented the preliminary analysis of our ongoing study on the immunity of patients with glioblastomas. Our first results comprise a limited studied population; therefore, far reaching conclusions may not be drawn. However, our data may be taken into consideration in order to design future larger relevant studies, in particular animal models with knock out techniques that may further clarify the role of importins in the maturation of DCs and in general in the immunological abnormalities observed in patients with glioblastomas.

**ACKNOWLEDGMENTS**

We thank Alexandra Breuer for her excellent assistance and technical support.

**REFERENCES**


Received: 20-08-2014; Accepted: 16-09-2014